NCT06767683Phase 2, phase 3Recruiting

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

Study sponsor: Alkermes, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2030-06Estimated
Enrollment · participants786Estimated
Source updated2026-11-18Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of Treatment-Emergent Adverse Events Time frame: Up to 100 Weeks. After: Measure: Incidence of Treatment-Emergent Adverse Events Time frame: Up to 248 Weeks.

Planned enrollment increased by 530 participants

Before: 256 participants (planned). After: 786 participants (planned).

Primary completion date changed

Before: Jun 2028. After: Jun 2030.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview